Main Uses and Benefits of Dolfen (Diclofenac)

Dolfen, containing the active ingredient diclofenac, belongs to a class of medications known as non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily used to manage symptoms associated with various inflammatory and painful conditions.

Primary Indications

• Arthritic Conditions: Diclofenac is commonly used to relieve pain, swelling, and joint stiffness caused by different types of arthritis, including rheumatoid arthritis and osteoarthritis.
• Acute Musculoskeletal Pain: It is effective in managing discomfort resulting from sprains, strains, and other soft tissue injuries.
• Inflammatory Pain: The medication is used to reduce inflammation and associated pain in conditions such as ankylosing spondylitis, which affects the spine.
• Post-Operative Recovery: It may be used to manage localized pain and inflammation following certain surgical procedures.

Therapeutic Benefits

• Reduction of Inflammation: By inhibiting the enzymes responsible for producing prostaglandins—chemicals in the body that signal pain and inflammation—diclofenac helps reduce swelling at the site of injury or disease.
• Pain Relief: Its analgesic properties help alleviate mild to moderate pain, improving the ability to perform daily activities.
• Improved Mobility: By reducing joint stiffness and pain associated with chronic conditions, it can help maintain or improve physical function and range of motion.

Mechanism of Action

Diclofenac works by targeting the cyclooxygenase (COX) enzymes. By blocking these enzymes, the medication decreases the synthesis of prostaglandins. This reduction in prostaglandin levels directly correlates to a decrease in the sensation of pain and the physical manifestations of inflammation, such as redness and heat.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Profile for Diclofenac (Systemic)

Official regulatory documents define strict exclusions and conditional use requirements for systemic diclofenac, primarily based on cardiovascular, gastrointestinal, and allergic risks.

---

Populations That Must Not Use Diclofenac (Contraindicated):

Category	Exclusion Condition
Allergy/Sensitivity	Known hypersensitivity to diclofenac, aspirin, or other NSAIDs (history of asthma, urticaria, or allergic-type reactions).
Cardiovascular Risk	Peri-operative pain treatment in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Cardiovascular Disease	Established congestive heart failure (NYHA Class II-IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease (EMA/UK MHRA).
Gastrointestinal	Active gastrointestinal bleeding, ulceration, or perforation.
Pregnancy	Pregnant women at 30 weeks gestation and later.

---

Populations Requiring Restricted or Conditional Use:

• Cardiovascular Risk Factors: Patients with uncontrolled hypertension, diabetes mellitus, hyperlipidaemia, or who smoke must use the drug only after careful risk assessment, generally at the lowest effective dose for the shortest duration.
• Organ Function: Patients with severe renal disease or severe hepatic impairment should use with caution or avoid use entirely unless the benefits are determined to outweigh the risk of worsening organ function.
• Age: Elderly patients are at greater risk for serious adverse events and require careful monitoring.
• Pediatric Patients: Safety and effectiveness are not established for the overall pediatric population; use is limited to specific age groups and formulations where data exists.

Interactions with other medicines and products

Official regulatory information regarding Dolfen (Diclofenac) defines specific drug and product combinations that require caution or are formally prohibited.

Formal Interaction Restrictions and Prohibitions

• Contraindicated Combinations: Diclofenac is strictly contraindicated for treating pain in the setting of perioperative Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other systemic NSAIDs is not recommended due to an elevated risk of serious gastrointestinal events.
• Bleeding Risk: Increased risk of hemorrhage is documented when Diclofenac is combined with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, or SSRIs/SNRIs. Close monitoring of coagulation status is required.

Pharmacokinetic and Efficacy Alterations

Interacting Substance Category	Official Documented Effect
Diuretics / ACE Inhibitors / ARBs	May reduce the antihypertensive or diuretic effects.
Lithium or Digoxin	Increased serum concentrations of the co-administered drug.
Voriconazole	Documented increase in Diclofenac plasma levels (Cmax/AUC).

Diclofenac may increase the concentration of drugs like Methotrexate and requires specific monitoring when combined with the CYP inhibitor Voriconazole. Furthermore, alcohol use is noted to increase the documented risk for serious GI bleeding. In specific populations, such as the elderly or volume-depleted patients, combining Diclofenac with ACE Inhibitors or ARBs is associated with an increased risk of renal function deterioration.

The action of Diclofenac is achieved through a coordinated influence on the body's chemical and electrical signaling systems, modulating heightened physiological activity.

Core Mechanism: Inhibiting Chemical Mediators

The drug’s main mechanism involves the competitive inhibition of Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By blocking these enzymes, Diclofenac prevents the conversion of arachidonic acid into prostaglandins, which are local chemical mediators of physiological responses. This molecular step modifies early processes in the inflammatory cascade, resulting in altered chemical signaling within the pathway.

Modulation of Neuronal Electrical Signals

Diclofenac exerts a secondary, non-prostaglandin-dependent mechanism involving the modulation of ion channels in neuronal membranes. This includes directly blocking voltage-gated sodium channels ( Na^+ channels) and modulating certain potassium channels ( K^+ channels), particularly in peripheral sensory neurons. This targeted pathway interference restricts ion flux, altering the characteristics of the action potential and modulating signal transmission within the nociceptive signaling pathway.

️ Central Modulation of Thermal Regulation

The molecule is able to penetrate the central nervous system ( CNS) to act directly on the hypothalamus. By inhibiting COX-2 activity centrally, Diclofenac blocks the local synthesis of PGE2 that normally influences the body's thermoregulatory set point. This central modulation influences the thermal control pathway, resulting in physiological processes that facilitate heat dissipation.

How to Use Diclofenac (Dolfen): Official Administration Guidelines

These guidelines detail the proper use and administration of diclofenac.

---

Administration Scope

Administration Detail	Official Instructions
Route of Administration	Oral, Rectal, Intramuscular (IM), Intravenous (IV), Topical (Gel/Solution).
Standard Oral Dosing	Typically 50 mg to 75 mg taken two or three times daily, not to exceed 150 mg per day (for most forms). Extended-release forms are typically 100 mg once daily.
Timing in Relation to Meals	Delayed-release tablets may be taken with food. Oral powder for solution and certain capsules (free acid) must be taken on an empty stomach.
Preparation Requirements	Oral powder must be dissolved in 1 to 2 ounces of water only and consumed immediately. IV concentrate must be diluted and buffered prior to infusion.

---

Special Procedural and Population Rules

• Tablet/Capsule Handling: Modified-release tablets (delayed or extended) must be swallowed whole and must not be crushed, broken, or chewed.
• Parenteral Use Limit: IM injection is for deep intragluteal use. Parenteral administration (IM/IV) should generally be limited to a maximum of two days, followed by a transition to oral or rectal forms if needed.
• Topical Application: Apply topical gels only to clean, intact skin. Do not apply occlusive dressings, external heat, or expose the treated area to sunlight.
• Population-Specific Dosing: For geriatric patients and those with low body weight, the lowest effective dosage should be used. Pediatric dosing is dependent on specific formulation and age, and many adult forms are not approved for younger children.

Research Evidence / Overview of Studies for Dolfen (Diclofenac)

Evidence for use in Low Back Pain

Research focused on short-term randomized controlled trials for adults with non-specific low back pain, applying in studies examining patient-reported experiences of pain intensity and function. Research highlights changes measured during the study period, showing that studies reported measurements of small, short-term changes in pain intensity scores when comparing the group studied to control groups. The long-term effects are not fully established beyond the short timeframes of the clinical trials, and data for certain groups remain insufficient, specifically concerning populations with more complex types of back pain.

---

Evidence for use in Rheumatoid Arthritis

Research was evaluated in adults with active, moderate to severe rheumatoid arthritis, exploring assessments of overall disease activity and specific joint tenderness or swelling counts in short to moderate-term controlled trials. Studies monitored how symptoms evolved in the observed populations, and data report patterns related to lower measured disease activity scores in some participants compared to measurements taken at the start of the study. The duration of observed changes is limited, and long-term outcomes regarding the progression of structural joint damage are not well characterized. Comparative evidence is lacking in relation to all other available management options.

---

Evidence for use in Osteoarthritis

The primary evidence comes from short-term randomized controlled trials, often lasting 4 to 12 weeks, which used in research exploring how symptoms change over time for symptomatic osteoarthritis of the knee or hip. Findings describe patterns observed in the studies where pain scores were reported to be lower in the studied groups compared to either the starting measurement or to a control group. There is limited information for long-term outcomes concerning the influence on the natural history of the condition. Data for certain groups remain insufficient, particularly for people with osteoarthritis in joints other than the knee or hip.

---

What is Still Uncertain about Dolfen (Diclofenac)

Across the research landscape, long-term effects are not fully established for any of the indications, as the majority of studies explored short-term outcomes related to physical discomfort. The consistency of findings were mixed across different studies, and sample sizes were modest in many trials. Comparative evidence is also lacking in certain areas, limiting the context needed to understand how the measured outcomes relate to other available management approaches. Evidence highlights what is known — and what is still uncertain.

Common questions about Dolfen (Diclofenac) (FAQ)

Q: What is Dolfen (Diclofenac) and what is it used for?

A: Dolfen is a brand name for the drug Diclofenac, which belongs to a class of medications called Nonsteroidal Anti-inflammatory Drugs (NSAIDs). It works by blocking certain natural substances in your body that cause inflammation. Diclofenac is primarily used to relieve pain, swelling, and joint stiffness associated with various conditions, including:

• Rheumatoid arthritis
• Osteoarthritis
• Ankylosing spondylitis
• Acute pain (like dental pain, menstrual cramps, or pain after surgery)

Q: How quickly does Dolfen (Diclofenac) start working?

A: The time it takes for Dolfen (Diclofenac) to start working depends on the formulation (e.g., immediate-release tablet, extended-release tablet, or capsule). Generally, most people start to feel the effects of pain relief within 30 minutes to an hour after taking an immediate-release oral dose. The full anti-inflammatory effect for long-term conditions like arthritis may take several days or up to two weeks of regular use to become noticeable.

Q: Can Dolfen (Diclofenac) be taken with other pain relievers?

A: Dolfen (Diclofenac) should not be taken with other NSAIDs. This includes common over-the-counter medications like Ibuprofen (e.g., Advil, Motrin) and Naproxen (e.g., Aleve), as well as prescription NSAIDs. Combining Diclofenac with other NSAIDs significantly increases the risk of serious side effects, particularly affecting the stomach (ulcers or bleeding) and the cardiovascular system.

However, it is generally safe to take Diclofenac with Acetaminophen (e.g., Tylenol) at recommended doses, as Acetaminophen works differently and is not an NSAID. Always consult a healthcare professional before combining pain medications.

Q: What are the common side effects of Dolfen (Diclofenac)?

A: The most common side effects associated with Dolfen (Diclofenac) typically involve the digestive system. These may include:

• Stomach pain
• Indigestion or heartburn
• Nausea
• Diarrhea or constipation

Other common side effects can include headache, dizziness, and mild skin rash. Many of these mild side effects often resolve as your body adjusts to the medication. If side effects persist or worsen, contact your healthcare provider.

Q: Is Dolfen (Diclofenac) safe for everyone?

A: No. Dolfen (Diclofenac), like all NSAIDs, is not safe for everyone and has several important contraindications (reasons it should not be used). You should not take Diclofenac if you have:

• A known allergy or hypersensitivity to Diclofenac, Aspirin, or other NSAIDs.
• A history of severe allergic reactions (such as asthma, hives, or swelling) after taking an NSAID.
• Active stomach or intestinal ulcers or recent gastrointestinal bleeding.
• Severe heart failure.
• Recently undergone coronary artery bypass graft (CABG) surgery.
• Are in the third trimester of pregnancy.

It should be used with caution in people with a history of heart disease, high blood pressure, kidney problems, or liver problems. A healthcare provider must review your full medical history before prescribing.

Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of diclofenac to maintain product stability and ensure safety.

• Storage Environment: Diclofenac products must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be protected from freezing, excessive heat, moisture, and direct light.

• Container and Handling: The product must be kept in its original, tightly closed container and should not be stored outside the permissible temperature range.

• Child Safety: All formulations must be stored out of the sight and reach of children and pets. Used topical patches, which still contain active medication, must be immediately folded so the adhesive layers stick together before disposal.

• Disposal: Unused or expired diclofenac must be disposed of according to local regulations, such as authorized take-back programs. The medicine should not be flushed down a toilet or sink due to environmental concerns.